Edition:
United States

Boston Scientific Corp (BSX)

BSX on New York Consolidated

23.90USD
17 Jan 2017
Change (% chg)

$0.08 (+0.34%)
Prev Close
$23.82
Open
$23.66
Day's High
$23.96
Day's Low
$23.63
Volume
8,601,621
Avg. Vol
8,755,737
52-wk High
$24.79
52-wk Low
$15.67

Select another date:

Mon, Nov 28 2016

BRIEF-Nevro files lawsuit for patent infringement against Boston Scientific in the U.S.

* Nevro files lawsuit for patent infringement against Boston Scientific in the U.S.

BRIEF-Boston Scientific acquires tissue resection device from Distal Access

* Boston Scientific Corp- specific terms of transaction were not disclosed

BRIEF-Boston Scientific's unit Falcon Merger extends offer for all shares of EndoChoice Holdings

* Says unit, Falcon Merger Corp has extended its previously announced tender offer for all shares of EndoChoice Holdings

BRIEF-Boston Scientific reports acquisition of the Lumenr tissue retractor system

* Boston Scientific announces acquisition of the lumenr tissue retractor system

Boston Scientific lifts 2016 revenue forecast after beat

Boston Scientific Corp's quarterly revenue beat analysts' estimates, boosted by higher demand for its heart devices, and the medical device maker raised its full-year forecast again.

RPT-UPDATE 1-Boston Scientific lifts 2016 revenue forecast after beat

Oct 26 Boston Scientific Corp's quarterly revenue beat analysts' estimates, boosted by higher demand for its heart devices, and the medical device maker raised its full-year forecast again.

BRIEF-Boston Scientific Q3 GAAP EPS $0.17

* Q4 earnings per share view $0.29, revenue view $2.15 billion -- Thomson Reuters I/B/E/S

Medical device maker Boston Scientific's net sales rise 11.5 pct

Oct 26 Boston Scientific Corp reported an 11.5 percent rise in quarterly net sales, boosted by higher demand for its heart devices.

Boston Scientific asks Supreme Court to toss $308 mln verdict in patent licensing spat

Boston Scientific Corp has asked the U.S. Supreme Court to overturn a $308 million Maryland state court jury verdict in a case over a patent licensing deal for implantable defibrillators, arguing that the state court ignored established patent law.

BRIEF-Ian Meredith to join Boston Scientific as executive VP, global chief medical officer

* Professor Ian Meredith to join Boston Scientific as executive vice president and global chief medical officer Source text for Eikon: Further company coverage:

Select another date: